« Return to News | R&D Trends | Drug Sponsors

Selventa and Janssen form research agreement

Monday, February 27, 2012 03:15 PM

Cambridge, Mass.-based Selventa, a personalized healthcare company focused on development of predictive biomarker panels, has formed a multi-year research agreement with Janssen R&D in immunological disease.

The agreement focuses on development of disease models using diverse biologic data to elaborate disease-relevant mechanisms and identify potential new drug discovery opportunities.

“We are very excited to have the opportunity to continue to work with Janssen R&D,” said David de Graaf, president and CEO of Selventa. “Building comprehensive disease models and investigating different molecular mechanisms may provide key data-driven foundations for appropriate selection of druggable mechanisms within a disease.”

Selventa utilizes molecular patient data and computational methods to derive mechanistic understanding of disease biology and unambiguously identify patient subsets based on their disease-driving mechanisms to enable personalized healthcare. This includes assessment of single and combination therapies, segmentation of potential responder and non-responder populations, evaluation of alternative indications, and optimization of proof-of-concept clinical trial design through stratification biomarker panels.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.